VENASEAL CLOSURE SYSTEM
Medtronic Vascular, Inc. · Decision date Feb 20, 2015
What did the FDA approve?
The FDA record P140018 lists an approval dated 2015-02-20 for the VenaSeal Closure System, submitted by Medtronic Vascular, Inc. under product code PJQ (agent, occluding, vascular, permanent) in the Cardiovascular specialty. The supplied fields show no supplement type or supplement reason, so the entry is described as an approval of the system itself rather than a later change to an existing approval.
The stated indication covers permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein, through endovascular embolization with coaptation, for adults with clinically symptomatic venous reflux diagnosed by duplex ultrasound. That wording is the sponsor's reported intended use; it is not independent proof of safety or clinical effectiveness, and the record gives no trial data or performance results.
FDA approval order statement
APPROVAL FOR THE VENASEAL CLOSURE SYSTEM. THIS DEVICE IS INDICATED FOR THE PERMANENT CLOSURE OF LOWER EXTREMITY SUPERFICIAL TRUNCAL VEINS, SUCH AS THE GREAT SAPHENOUS VEIN (GSV), THROUGH ENDOVASCULAR EMBOLIZATION WITH COAPTATION. VENASEAL IS INTENDED FOR USE IN ADULTS WITH CLINICALLY SYMPTOMATIC VENOUS REFLUX AS DIAGNOSED BY DUPLEX ULTRASOUND (DUS).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 20, 2015
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140018
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Vascular, Inc.
- Product code
- PJQ
- Decision code
- APPR
- Decision date
- Feb 20, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, occluding, vascular, permanent.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- PJQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P140018 received
Application receipt date recorded by FDA.
P140018 · FDA decision
APPR
P140018/S050 · Related supplement
VenaSeal Closure System
Timeline entries are records held by MedtechLedger for P140018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VenaSeal Closure SystemP140018/S050 | Medtronic Vascular, Inc. | PMA supplement | Oct 15, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P140018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records